Jochen H Weishaupt
Overview
Explore the profile of Jochen H Weishaupt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
5988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wischnewski S, Thawel T, Ikenaga C, Kocharyan A, Lerma-Martin C, Zulji A, et al.
Nat Aging
. 2024 Jun;
4(7):969-983.
PMID: 38834884
Inclusion body myositis (IBM) is the most prevalent inflammatory muscle disease in older adults with no effective therapy available. In contrast to other inflammatory myopathies such as subacute, immune-mediated necrotizing...
12.
Dash B, Freischmidt A, Weishaupt J, Hermann A
Hum Mol Genet
. 2024 Apr;
33(15):1300-1314.
PMID: 38676626
MicroRNAs (miRNAs) are a subset of small non-coding single-stranded RNA molecules involved in the regulation of post-transcriptional gene expression of a variety of transcript targets. Therefore altered miRNA expression may...
13.
Brenner D, Sieverding K, Srinidhi J, Zellner S, Secker C, Yilmaz R, et al.
J Exp Med
. 2024 Mar;
221(5).
PMID: 38517332
Heterozygous mutations in the TBK1 gene can cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The majority of TBK1-ALS/FTD patients carry deleterious loss-of-expression mutations, and it is still unclear...
14.
Schuster J, Dreyhaupt J, Monkemoller K, Dupuis L, Dieterle S, Weishaupt J, et al.
Eur J Neurol
. 2024 Jan;
31(4):e16204.
PMID: 38240416
Background And Purpose: In 2016, we concluded a randomized controlled trial testing 1 mg rasagiline per day add-on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article...
15.
Ramachandran S, Grozdanov V, Leins B, Kandler K, Witzel S, Mulaw M, et al.
Front Immunol
. 2023 Aug;
14:1193507.
PMID: 37545536
Background: Dysregulation of the immune system in amyotrophic lateral sclerosis (ALS) includes changes in T-cells composition and infiltration of T cells in the brain and spinal cord. Recent studies have...
16.
Brockmann S, Buck E, Casoli T, Meirelles J, Ruf W, Fabbietti P, et al.
Hum Genomics
. 2023 Jul;
17(1):70.
PMID: 37507754
Background: ALS is a heterogeneous disease in which different factors such as mitochondrial phenotypes act in combination with a genetic predisposition. This study addresses the question of whether homoplasmic (total...
17.
Hebestreit S, Schwahn J, Sandikci V, Maros M, Valkadinov I, Yilmaz R, et al.
Neurogenetics
. 2023 Jun;
24(3):209-213.
PMID: 37341843
Primary familial brain calcification (PFBC; formerly Fahr's disease) and early-onset Alzheimer's disease (EOAD) may share partially overlapping pathogenic principles. Although the heterozygous loss-of-function mutation c.1523 + 1G > T in...
18.
Ruf W, Boros M, Freischmidt A, Brenner D, Grozdanov V, de Meirelles J, et al.
Brain Commun
. 2023 May;
5(3):fcad152.
PMID: 37223130
Therapy of motoneuron diseases entered a new phase with the use of intrathecal antisense oligonucleotide therapies treating patients with specific gene mutations predominantly in the context of familial amyotrophic lateral...
19.
Kuhlwein J, Ruf W, Kandler K, Witzel S, Lang C, Mulaw M, et al.
Cell Mol Life Sci
. 2023 Apr;
80(5):131.
PMID: 37095391
Amyotrophic Lateral Sclerosis (ALS) is a complex and incurable neurodegenerative disorder in which genetic and epigenetic factors contribute to the pathogenesis of all forms of ALS. The interplay of genetic...
20.
Meyer T, Schumann P, Weydt P, Petri S, Koc Y, Spittel S, et al.
Muscle Nerve
. 2023 Mar;
67(6):515-521.
PMID: 36928619
Introduction/aims: In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1-ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently...